NHS England has published an anonymised list of \u2018outliers' which can be found at:<\/p>
<\/p>
www.england.nhs.uk/wp-content/uploads/2014/02/gp-gms-practices.pdf<\/p>
<\/p>
Because the information is commercially sensitive, details that could identify individual practices have not been released.<\/p>
<\/p>
The Minimum Practice Income Guarantee is being phased out over a period of seven years because it is inequitable, and the money released will be reinvested into basic payments made to all General Medical Services practices.<\/p>
<\/strong><\/p> NHS England is supporting the most affected practices.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-06-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-16T13:40:30.0616303Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "General Practitioners"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, which GP practices have been identified by NHS England as potentially losing more than £3 per patient in 2014-15 following the withdrawal of the Minimum Practice Income Guarantee.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
], "uin" : "200213"}
, {"_about" : "http://data.parliament.uk/resources/61303", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61303/answer", "answerText" : {"_value" : " Overall patient satisfaction is driven by a range of factors, including accessing a general practitioner (GP) appointment at a convenient time, ability to see a preferred GP and the quality of the conversation with the GP.<\/p> <\/p> The Government recognises the importance of timely access to general practice. The PM Challenge Fund has allocated £50 million to pilot ways to improve access around the country, to give GPs the flexibility to meet the needs of the local population.<\/p> <\/p> In addition, the new GP contract introduced a new Enhanced Service, which includes a commitment to same day phone consultations with a professional in the GP surgery, where necessary, for the most at risk in the population.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-06-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-16T13:27:12.2505444Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "General Practitioners: Standards"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect of being able to access a GP appointment within 48 hours on levels of patient satisfaction.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
], "uin" : "200214"}
, {"_about" : "http://data.parliament.uk/resources/61314", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61314/answer", "answerText" : {"_value" : " In 2010, responding to Professor Sir Ian Gilmore's review into extending entitlement to free prescriptions to all those with a long-term condition, the Government made clear that in light of the challenging financial context, no changes would be made to the current list of exemptions. Prescription charges in England raise valuable income, in the region of £450 million each year, which helps the National Health Service to maintain vital services for patients.<\/p> <\/p> The extensive system of exemption arrangements, including for those on low incomes who may struggle to pay for their prescriptions, which is in place means that around 90% of all prescription items are already dispensed free of charge. Prescription Prepayment Certificates (PPCs) are also available for those who have to pay NHS prescription charges and need multiple prescriptions. This is the fifth year the cost of an annual certificate, and the third year the cost of a three month certificate, have been frozen. Both certificates will also remain at £104 and £29.10 respectively, next year. There is no limit to the number of items that can be obtained through a PPC. The annual certificate benefits anyone needing more than 12 items a year, and the three month certificate anyone needing more than three items in that three month period.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-06-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-16T13:38:11.3884577Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cystic Fibrosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will review prescription charges for adults with cystic fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
, "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
], "uin" : "200281"}
, {"_about" : "http://data.parliament.uk/resources/61324", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61324/answer", "answerText" : {"_value" : " As part of the response to the issues in Mid-Staffordshire hospital, and following the recommendations of the Francis report, many trusts have increased agency spend in the short-term to protect patients and improve patient care. Over the longer term, a key objective for the NHS is to keep agency spend to a minimum, an increase in the number of permanent front-line staff is vital to both improving patient care and delivering value for money. The number of frontline clinical staff has increased by more than 16,300 since 2010.<\/p> <\/p> In 2013-14, NHS foundation trusts planned to spend £523 million on agency and contract staff and spent £1,373.0 million. NHS trusts spent £1,209.1 million, how much they planned to spend is not available.<\/p> <\/p> Sources: for NHS trusts \u2013 unaudited data in NHS trust summarisation schedules; for NHS foundation trusts \u2013 quarterly monitoring information.<\/p> <\/p> Plans are in place in Better Procurement to reduce by £450 million spend on agency and contract staff by the end of 2016.<\/p> <\/p> NHS Trusts spent £1,209.1 million on agency and contract staff n 2013/14.<\/p> <\/p> Source: Unaudited data in NHS Trust Summarisation Schedules.<\/p> <\/p> Amounts for 2009-10 to 2012-13 were not separately identified from other non-permanent staff.<\/p> <\/p> Spend by NHS Foundation Trusts on agency and contract staff is in the following table.<\/p> <\/p> Year<\/p><\/td> £ million<\/p><\/td><\/tr> 2009/10<\/p><\/td> 764.1<\/p><\/td><\/tr> 2010/11<\/p><\/td> 854.7<\/p><\/td><\/tr> 2011/12<\/p><\/td> 907.0<\/p><\/td><\/tr> 2012/13<\/p><\/td> 1,101.0<\/p><\/td><\/tr> 2013/14<\/p><\/td> 1,373.0<\/p><\/td><\/tr><\/tbody><\/table> <\/em><\/p> Notes<\/em>: For 2009/10 - 2012/13 actual figures are based on gross staff costs as per notes in the NHS FT consolidated accounts. The figures from the consolidated accounts may differ to the Board reports due to adjustments made on redundancy, early retirement, capitalisation of staff costs and costs of R&D staff. 2013/14 figures are from quarterly monitoring information.<\/p> <\/p> Information available about spend on all staff is set out in the tables below.<\/p> <\/p> NHS Trusts<\/p> <\/p> Year<\/p><\/td> £ million<\/p><\/td><\/tr> 2009/10<\/p><\/td> 18,225.1<\/p><\/td><\/tr> 2010/11<\/p><\/td> 18,929.5<\/p><\/td><\/tr> 2011/12<\/p><\/td> 19,839.5<\/p><\/td><\/tr> 2012/13<\/p><\/td> 19,344.7<\/p><\/td><\/tr><\/tbody><\/table> <\/em><\/p> Source: NHS (England) Summarised Accounts 2009/10, 2010/11; NHS Trust Audited Summarisation Schedules 2011/12, 2012/13. <\/em><\/p> <\/em><\/p> Note: <\/em>Total staff costs for 2013/14 are not yet available.<\/p> <\/p> NHS Foundation Trusts<\/p> <\/p> Year<\/p><\/td> £ million<\/p><\/td><\/tr> 2009/10<\/p><\/td> 17,599.7<\/p><\/td><\/tr> 2010/11<\/p><\/td> 19,442.9<\/p><\/td><\/tr> 2011/12<\/p><\/td> 23,046.0<\/p><\/td><\/tr> 2012/13<\/p><\/td> 24,709.0<\/p><\/td><\/tr> 2013/14<\/p><\/td> 26,246.0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Notes<\/em>: For 2009/10 - 2012/13 actual figures are based on gross staff costs as per notes in the NHS FT consolidated accounts. The figures from the consolidated accounts may differ to the Board reports due to adjustments made on redundancy, early retirement, capitalisation of staff costs and costs of R&D staff. 2013/14 figures are from quarterly monitoring information.<\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-06-16", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "200212"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-16T16:51:14.9133499Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Staff"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much NHS trusts have spent (a) on agency and contract staff and (b) on all staff in each financial year since 2009-10.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "200211"}
, {"_about" : "http://data.parliament.uk/resources/61325", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61325/answer", "answerText" : {"_value" : " As part of the response to the issues in Mid-Staffordshire hospital, and following the recommendations of the Francis report, many trusts have increased agency spend in the short-term to protect patients and improve patient care. Over the longer term, a key objective for the NHS is to keep agency spend to a minimum, an increase in the number of permanent front-line staff is vital to both improving patient care and delivering value for money. The number of frontline clinical staff has increased by more than 16,300 since 2010.<\/p> <\/p> In 2013-14, NHS foundation trusts planned to spend £523 million on agency and contract staff and spent £1,373.0 million. NHS trusts spent £1,209.1 million, how much they planned to spend is not available.<\/p> <\/p> Sources: for NHS trusts \u2013 unaudited data in NHS trust summarisation schedules; for NHS foundation trusts \u2013 quarterly monitoring information.<\/p> <\/p> Plans are in place in Better Procurement to reduce by £450 million spend on agency and contract staff by the end of 2016.<\/p> <\/p> NHS Trusts spent £1,209.1 million on agency and contract staff n 2013/14.<\/p> <\/p> Source: Unaudited data in NHS Trust Summarisation Schedules.<\/p> <\/p> Amounts for 2009-10 to 2012-13 were not separately identified from other non-permanent staff.<\/p> <\/p> Spend by NHS Foundation Trusts on agency and contract staff is in the following table.<\/p> <\/p> Year<\/p><\/td> £ million<\/p><\/td><\/tr> 2009/10<\/p><\/td> 764.1<\/p><\/td><\/tr> 2010/11<\/p><\/td> 854.7<\/p><\/td><\/tr> 2011/12<\/p><\/td> 907.0<\/p><\/td><\/tr> 2012/13<\/p><\/td> 1,101.0<\/p><\/td><\/tr> 2013/14<\/p><\/td> 1,373.0<\/p><\/td><\/tr><\/tbody><\/table> <\/em><\/p> Notes<\/em>: For 2009/10 - 2012/13 actual figures are based on gross staff costs as per notes in the NHS FT consolidated accounts. The figures from the consolidated accounts may differ to the Board reports due to adjustments made on redundancy, early retirement, capitalisation of staff costs and costs of R&D staff. 2013/14 figures are from quarterly monitoring information.<\/p> <\/p> Information available about spend on all staff is set out in the tables below.<\/p> <\/p> NHS Trusts<\/p> <\/p> Year<\/p><\/td> £ million<\/p><\/td><\/tr> 2009/10<\/p><\/td> 18,225.1<\/p><\/td><\/tr> 2010/11<\/p><\/td> 18,929.5<\/p><\/td><\/tr> 2011/12<\/p><\/td> 19,839.5<\/p><\/td><\/tr> 2012/13<\/p><\/td> 19,344.7<\/p><\/td><\/tr><\/tbody><\/table> <\/em><\/p> Source: NHS (England) Summarised Accounts 2009/10, 2010/11; NHS Trust Audited Summarisation Schedules 2011/12, 2012/13. <\/em><\/p> <\/em><\/p> Note: <\/em>Total staff costs for 2013/14 are not yet available.<\/p> <\/p> NHS Foundation Trusts<\/p> <\/p> Year<\/p><\/td> £ million<\/p><\/td><\/tr> 2009/10<\/p><\/td> 17,599.7<\/p><\/td><\/tr> 2010/11<\/p><\/td> 19,442.9<\/p><\/td><\/tr> 2011/12<\/p><\/td> 23,046.0<\/p><\/td><\/tr> 2012/13<\/p><\/td> 24,709.0<\/p><\/td><\/tr> 2013/14<\/p><\/td> 26,246.0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Notes<\/em>: For 2009/10 - 2012/13 actual figures are based on gross staff costs as per notes in the NHS FT consolidated accounts. The figures from the consolidated accounts may differ to the Board reports due to adjustments made on redundancy, early retirement, capitalisation of staff costs and costs of R&D staff. 2013/14 figures are from quarterly monitoring information.<\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-06-16", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "200211"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-16T16:51:15.0413074Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Temporary Employment"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much NHS trusts (a) planned to spend and (b) spent on agency and contract staff in 2013-14.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "200212"}
, {"_about" : "http://data.parliament.uk/resources/61332", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61332/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) has advised that providing all the information in the format requested would incur disproportionate cost.<\/p> <\/p> Information about technology appraisals where NICE has recommended a technology only in circumstances in which a patient has not been treated with a previously recommended technology can be found within each published technology appraisal on NICE's website at:<\/p> <\/p> www.nice.org.uk<\/p> <\/p> Information about where NICE has considered or made recommendations regarding the sequential use of technologies can also be found within each published technology appraisal on the website.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-06-18", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "200234"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-18T15:07:41.9801893Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, in which single or multiple technology appraisals for pharmacological treatments for cancer the National Institute for Health and Care Excellence (NICE) has considered the sequential use of the appraised technology with another available treatment; and whether in each such appraisal this resulted in a recommendation on sequential use in each year since NICE was established.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1518", "label" : {"_value" : "Biography information for Mr David Burrowes"}
}
, "tablingMemberConstituency" : {"_value" : "Enfield, Southgate"}
, "tablingMemberPrinted" : [{"_value" : "Mr David Burrowes"}
], "uin" : "200238"}
, {"_about" : "http://data.parliament.uk/resources/61333", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61333/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) has advised that providing all the information in the format requested would incur disproportionate cost.<\/p> <\/p> Information about technology appraisals where NICE has recommended a technology only in circumstances in which a patient has not been treated with a previously recommended technology can be found within each published technology appraisal on NICE's website at:<\/p> <\/p> www.nice.org.uk<\/p> <\/p> Information about where NICE has considered or made recommendations regarding the sequential use of technologies can also be found within each published technology appraisal on the website.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-06-18", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "200238"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-18T15:07:41.8830863Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended only for patients who have not been treated with a previously appraised drug.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1518", "label" : {"_value" : "Biography information for Mr David Burrowes"}
}
, "tablingMemberConstituency" : {"_value" : "Enfield, Southgate"}
, "tablingMemberPrinted" : [{"_value" : "Mr David Burrowes"}
], "uin" : "200234"}
, {"_about" : "http://data.parliament.uk/resources/61334", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61334/answer", "answerText" : {"_value" : " The consideration of end of life criteria was introduced into the National Institute for Health and Care Excellence's (NICE) technology appraisal process in January 2009. NICE has advised that it has recommended the following treatments for prostate, lung, bowel and kidney cancer under its technology appraisal programme where the end of life criteria were applied. No treatments for breast cancer have been recommended under the end of life criteria.<\/p> <\/p> Cancer<\/p><\/td> Appraisal<\/p><\/td> Technolo-gy appraisal<\/p><\/td><\/tr> Prostate<\/p><\/td> abiraterone in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen<\/p><\/td> TA259<\/p><\/td><\/tr> Lung<\/p><\/td> oral topotecan for small cell lung cancer<\/p><\/td> TA184<\/p><\/td><\/tr> pemetrexed (maintenance treatment) for non-small cell lung cancer<\/p><\/td> TA190<\/p><\/td><\/tr> Bowel<\/p><\/td> sunitinib for gastrointestinal stromal tumours<\/p><\/td> TA179<\/p><\/td><\/tr> Kidney<\/p><\/td> sunitinib (first-line) for renal cell carcinoma<\/p><\/td> TA169<\/p><\/td><\/tr> pazopanib for the first-line treatment of advanced renal cell carcinoma<\/p><\/td> TA215<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source<\/em>: National Institute for Health and Care Excellence<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-06-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-18T15:11:00.1141425Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence (NICE) has recommended for (i) prostate cancer, (ii) lung cancer, (iii) bowel cancer, (iv) breast cancer and (v) kidney cancer through either single or multiple technology appraisals and under the end of life criteria in each year since NICE was established.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1518", "label" : {"_value" : "Biography information for Mr David Burrowes"}
}
, "tablingMemberConstituency" : {"_value" : "Enfield, Southgate"}
, "tablingMemberPrinted" : [{"_value" : "Mr David Burrowes"}
], "uin" : "200233"}
, {"_about" : "http://data.parliament.uk/resources/61335", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61335/answer", "answerText" : {"_value" : " This information is not collected by the Department or NHS England.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-06-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-18T15:04:47.4586795Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many patients have not received homecare medicines and products on time for treatment of (a) cystic fibrosis, (b) HIV and (c) rheumatoid arthritis in the last year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3953", "label" : {"_value" : "Biography information for Jason McCartney"}
}
, "tablingMemberConstituency" : {"_value" : "Colne Valley"}
, "tablingMemberPrinted" : [{"_value" : "Jason McCartney"}
], "uin" : "200204"}
, {"_about" : "http://data.parliament.uk/resources/61336", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/61336/answer", "answerText" : {"_value" : " It is estimated that between 2009 and 2013 approximately 49,000 forms were returned to registered medical practitioners (RMPs) for further information and clarification.<\/p> <\/p> Form HSA4 already requires information to be provided as to whether the two certifying RMPs saw and/or examined the pregnant woman.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2014-06-18", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "200274"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-06-18T15:36:17.6132667Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Abortion"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many HSA4 certificates his Department has returned to terminating doctors pending completion in the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1566", "label" : {"_value" : "Biography information for Daniel Kawczynski"}
}
, "tablingMemberConstituency" : {"_value" : "Shrewsbury and Atcham"}
, "tablingMemberPrinted" : [{"_value" : "Daniel Kawczynski"}
], "uin" : "200273"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpCreated=2014-06-11T23%3A56%3A37.097Z&AnsweringBody.=Department+of+Health&max-answer.questionFirstAnswered.=2014-11-03T11%3A55%3A38.2788256Z", "page" : 0, "startIndex" : 1, "totalResults" : 697, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}